Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

In Mantle Cell Lymphoma, Velcade After Stem Cell Transplant Delays Disease Progression

May 16th 2020

Velcade not only delays the progression of mantle cell lymphoma when given after stem cell transplant but also prolongs survival. However, the treatment comes with significant side effects.

High-Dose Chemotherapy Regimen Shows Good Response in Certain Patients with Mantle Cell Lymphoma

April 7th 2020

Patients with mantle cell lymphoma who were eligible for stem cell transplant saw a 97% overall response rate to a three-drug regimen, according to findings from two clinical trials.

CAR-T Cell Therapy Shows Promise in Patients with Mantle Cell Lymphoma

April 6th 2020

At one-year follow-up, phase 2 clinical trial results showed that most patients with relapsed or treatment resistant mantle cell lymphoma responded to chimeric antigen receptor (CAR)-T cell therapy.

Speaking Out: Treatment Options May Expand in Mantle Cell Lymphoma

March 5th 2020

An expert sheds light on the latest therapies in clinical trials and promising drug combinations to thwart the aggressive disease.

BTK Inhibitors Offer Improved Response Over Chemotherapy in Mantle Cell Lymphoma

February 28th 2020

Patients with relapsed/refractory mantle cell lymphoma saw more favorable responses with the BTK inhibitor Imbruvica (ibrutinib) than with chemotherapy, according to nearly a decade of data.

Immune-Based Therapies Emerge in Mantle Cell Lymphoma

February 24th 2020

Patients with the aggressive blood cancer can turn to immunotherapies like CAR-T cell therapy when disease recurs or becomes resistant.

FDA Grants Priority Review to CAR-T Cell Therapy for Mantle Cell Lymphoma

February 11th 2020

The Food and Drug Administration granted a priority review to KTE-X19 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

The Use of Immunotherapy in Blood Cancer Treatment

February 7th 2020

Exciting Treatment Options Being Developed in Multiple Myeloma

February 7th 2020

Genetic Sequencing in Chronic Lymphocytic Leukemia

February 7th 2020

The Basics of Mantle Cell Lymphoma

February 7th 2020

Joining a Clinical Trial

February 7th 2020

CURE's Clinical Trial Corner: January 2020

January 30th 2020

Here is a list of the recent trial initiations that occurred within the cancer space in January.

BTK Inhibitor Use Proves Beneficial in Mantle Cell Lymphoma Treatment

January 8th 2020

Typically, the longer a patient with cancer is exposed to a drug the more side effects they experience, but in the case of Imbruvica, the opposite appears to be true for patients with MCL.

Phase 3 GRAVITAS-301 Study Fails to Improve Overall Responses in GVHD

January 7th 2020

The pivotal phase 3 GRAVITAS-301 study – designed to evaluate itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease – failed to meet its primary endpoint of improving overall response rates.

Patients with MCL Who Exhausted Treatment Options Have a Potential New Therapy

January 6th 2020

Treatment with a CAR-T cell therapy showed promise in patients with mantle cell lymphoma, potentially leading to a new option for a group of individuals who have exhausted other options.

CAR-T Cell Therapies Could Change the Mantle Cell Lymphoma Landscape

December 14th 2019

However, the recent addition of new chemotherapy-free options such as chimeric antigen receptor (CAR)-T cell therapy could offer hope for patients with mantle cell lymphoma who develop resistance to chemotherapy-based treatment.

BTK Inhibitors Could Replace Chemotherapy in Mantle Cell Lymphoma Treatment

December 13th 2019

While chemotherapy is widely used in the frontline treatment of mantle cell lymphoma (MCL), earlier use of BTK inhibitors such as Imbruvica (ibrutinib) may soon make chemotherapy obsolete for some patients, according to new data presented at the 2019 American Society of Hematology (ASH) Annual Meeting.

What Patients With Mantle Cell Lymphoma Should Know About the FDA's Approval of Brukinsa

November 21st 2019

The Food and Drug Administration approved Brukinsa to treat relapsed and refractory mantle cell lymphoma, but what does this mean for patients?

Precision Medicine and Personalized Treatments Shifting the Tide in Mantle Cell Lymphoma

November 18th 2019

While resistance can often make it a challenge to treat mantle cell lymphoma, therapies have come a long way in recent years thanks to the emergence of personalized treatment and the use of BTK inhibitors, according to one expert.

Promising Early Clinical Trial Results Prompt Study Expansion to Include Patients with Mantle Cell Lymphoma

November 18th 2019

Researchers are expanding a clinical trial to include more patients with mantle cell lymphoma after some patients given the combination of medications under investigation showed no signs of cancer after treatment.

FDA Approves Brukinsa for Patients with Relapsed and Refractory Mantle Cell Lymphoma

November 15th 2019

The Food and Drug Administration has approved Brukinsa to treat patients with mantle cell lymphoma whose disease has stopped responding to other medications or has recurred.

In Memoriam: Dr. Thomas Weber

September 18th 2019

Dr. Thomas Weber has died following a ‘short but fierce’ fight with mantle cell lymphoma.

Thousands Celebrate Cancer Survivorship at Annual Life and Liberty Event

September 16th 2019

Patients and survivors shared messages of hope and enjoyed an evening of fun at the 11th annual celebration sponsored by Hackensack Meridian Health.

Family History Raises Risk of Blood Cancer

September 16th 2019

Having a parent, sibling or child with blood cancer raises an individual’s risk of also receiving a blood cancer diagnosis, according to the results of a large European study.

Older Patients With Mantle Cell Lymphoma Benefit Most From Individualized Treatment

September 13th 2019

While emerging therapies for mantle cell lymphoma (MCL) continue to shape the treatment landscape, no key standard currently exists, says one expert – particularly for older patients, who benefit most from a treatment approach that has been tailored to fit them and their disease.

Emerging Treatments for Mantle Cell Lymphoma

September 10th 2019

BTK inhibitors and CAR-T cell therapies for mantle cell lymphoma help to expand the treatment landscape for patients.

Novel Agents May Lead to a Chemo-Free Future for Patients With Mantle Cell Lymphoma

September 6th 2019

One expert discusses the current treatment options for patients with mantle cell lymphoma as well as the potential shift away from chemotherapy in the future.

Study Unveils Family Risk for Certain Types of Blood Cancer

August 14th 2019

Those with a first-degree relative diagnosed with certain blood cancers may be at an increased risk for developing the disease themselves.

Study Highlights Need for Frailty Testing Among Older Adults with Blood Cancer

August 5th 2019

A slower walking pace among older adults with blood cancer can be a sign of frailty – which could be useful to know when tailoring one’s care to increase survival and lower hospitalizations.